Compounds > teicoplanin aglycone
Page last updated: 2024-11-12

teicoplanin aglycone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

teicoplanin aglycone: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID135887790
MeSH IDM0174337
PubMed CID16154789
CHEMBL ID2348244
CHEBI ID135904
MeSH IDM0174337

Synonyms (20)

Synonym
td-a3
teicoplanin aglycone
a41030b
ristomycin a aglycone, 7-demethyl-64-o-demethyl-19-deoxy-22,31-dichloro-
7-demethyl-64-o-demethyl-19-deoxy-22,31-dichlororistomycin a aglycone
antibiotic l 17392
antibiotic a 41030b
89139-42-4
unii-3e6ib3p0lt
3e6ib3p0lt ,
ristomycin a aglycone, 22,31-dichloro-7-demethyl-64-o-demethyl-19-deoxy-
ristomycin a aglycone, 22, 31-dichloro-7-demethyl-64-o-demethyl-19-deoxy-
teicoplanin aglycon
amino-dichloro-heptahydroxy-hexaoxo-[?]carboxylic acid
CHEBI:135904
aglycon
CHEMBL2348244
aglucoteicoplanin
deglucoteicoplanin
22,31-dichloro-7-demethyl-64-o-demethyl-19-deoxyristomycin a aglycone
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
oligopeptideA peptide containing a relatively small number of amino acids.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (64)

Assay IDTitleYearJournalArticle
AID1201119Antiviral activity against Influenza A virus (A/Hong Kong/7/1987(H3N2)) infected in MDCK cells assessed as reduction of virus-induced cytopathic effect after 72 hrs by microscopic analysis2015European journal of medicinal chemistry, Apr-13, Volume: 94A few atoms make the difference: synthetic, CD, NMR and computational studies on antiviral and antibacterial activities of glycopeptide antibiotic aglycon derivatives.
AID201602Minimum inhibitory concentration against Staphylococcus haemolyticus L 6021992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
Synthesis and antibacterial activity of a series of basic amides of teicoplanin and deglucoteicoplanin with polyamines.
AID113353Subcutaneously administration into mice infected with Streptococcus pyogenes C 2031989Journal of medicinal chemistry, Nov, Volume: 32, Issue:11
Synthesis and biological properties of N63-carboxamides of teicoplanin antibiotics. Structure-activity relationships.
AID207533Minimal inhibitory concentration of compound against Staphylococcus aureus Tour determined in iso-sensitest broth with an inoculum of 10e4 cfu/mL1989Journal of medicinal chemistry, Feb, Volume: 32, Issue:2
Deaminoteicoplanin and its derivatives. Synthesis, antibacterial activity, and binding strength to Ac-D-Ala-D-Ala.
AID210411Minimal inhibitory concentration of compound against Streptococcus pyogenes C2031989Journal of medicinal chemistry, Feb, Volume: 32, Issue:2
Deaminoteicoplanin and its derivatives. Synthesis, antibacterial activity, and binding strength to Ac-D-Ala-D-Ala.
AID227928Association constant of compound was evaluated at pH 91989Journal of medicinal chemistry, Apr, Volume: 32, Issue:4
Synthesis and biological evaluation of de(acetylglucosaminyl)didehydrodeoxy derivatives of teicoplanin antibodies.
AID206514Minimum inhibitory concentration against Staphylococcus hominis L1070 evaluated in vitro1989Journal of medicinal chemistry, Apr, Volume: 32, Issue:4
Synthesis and biological evaluation of de(acetylglucosaminyl)didehydrodeoxy derivatives of teicoplanin antibodies.
AID68069Antibacterial activity against glycopeptide susceptible Enterococcus faecium 568 strain2003Journal of medicinal chemistry, Mar-27, Volume: 46, Issue:7
Role of the glycopeptide framework in the antibacterial activity of hydrophobic derivatives of glycopeptide antibiotics.
AID66902Antibacterial activity against glycopeptide resistant Enterococcus faecalis 560 strain2003Journal of medicinal chemistry, Mar-27, Volume: 46, Issue:7
Role of the glycopeptide framework in the antibacterial activity of hydrophobic derivatives of glycopeptide antibiotics.
AID209777Minimum inhibitory concentration against Streptococcus pyogenes C 203 evaluated in vitro1989Journal of medicinal chemistry, Apr, Volume: 32, Issue:4
Synthesis and biological evaluation of de(acetylglucosaminyl)didehydrodeoxy derivatives of teicoplanin antibodies.
AID201604In vitro minimum inhibitory concentration against Staphylococcus hemolyticus 602 cell line1989Journal of medicinal chemistry, Nov, Volume: 32, Issue:11
Synthesis and biological properties of N63-carboxamides of teicoplanin antibiotics. Structure-activity relationships.
AID206359Minimum inhibitory concentration against Staphylococcus epidermis ATCC 12228 evaluated in vitro1989Journal of medicinal chemistry, Apr, Volume: 32, Issue:4
Synthesis and biological evaluation of de(acetylglucosaminyl)didehydrodeoxy derivatives of teicoplanin antibodies.
AID208133In vitro minimum inhibitory concentration against Streptococcus pneumoniae UC411989Journal of medicinal chemistry, Nov, Volume: 32, Issue:11
Synthesis and biological properties of N63-carboxamides of teicoplanin antibiotics. Structure-activity relationships.
AID207011Antibacterial activity against glycopeptide intermediate resistant Staphylococcus aureus 3798 strain2003Journal of medicinal chemistry, Mar-27, Volume: 46, Issue:7
Role of the glycopeptide framework in the antibacterial activity of hydrophobic derivatives of glycopeptide antibiotics.
AID209060Minimal inhibitory concentration of compound against Streptococcus epidermidis ATCC 122281989Journal of medicinal chemistry, Feb, Volume: 32, Issue:2
Deaminoteicoplanin and its derivatives. Synthesis, antibacterial activity, and binding strength to Ac-D-Ala-D-Ala.
AID209722Minimal inhibitory concentration of compound against Streptococcus pneumoniae UC411989Journal of medicinal chemistry, Feb, Volume: 32, Issue:2
Deaminoteicoplanin and its derivatives. Synthesis, antibacterial activity, and binding strength to Ac-D-Ala-D-Ala.
AID739991Antimicrobial activity against Staphylococcus aureus ATCC 259232013Journal of medicinal chemistry, May-23, Volume: 56, Issue:10
Probing the role of the vancomycin e-ring aryl chloride: selective divergent synthesis and evaluation of alternatively substituted E-ring analogues.
AID206500Minimum inhibitory concentration against Staphylococcus haemolyticus L1520 evaluated in vitro1989Journal of medicinal chemistry, Apr, Volume: 32, Issue:4
Synthesis and biological evaluation of de(acetylglucosaminyl)didehydrodeoxy derivatives of teicoplanin antibodies.
AID202115Efficacy of compound administered subcutaneously against Streptococcus pyogenes L 49 Septicemia in mouse1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
Synthesis and antibacterial activity of a series of basic amides of teicoplanin and deglucoteicoplanin with polyamines.
AID208452Minimum inhibitory concentration against Streptococcus pneumoniae UC 41 evaluated in vitro1989Journal of medicinal chemistry, Apr, Volume: 32, Issue:4
Synthesis and biological evaluation of de(acetylglucosaminyl)didehydrodeoxy derivatives of teicoplanin antibodies.
AID209237In vitro minimum inhibitory concentration against Streptococcus faecalis ATCC 70801989Journal of medicinal chemistry, Nov, Volume: 32, Issue:11
Synthesis and biological properties of N63-carboxamides of teicoplanin antibiotics. Structure-activity relationships.
AID66903Antibacterial activity against glycopeptide susceptible Enterococcus faecalis 559 strain2003Journal of medicinal chemistry, Mar-27, Volume: 46, Issue:7
Role of the glycopeptide framework in the antibacterial activity of hydrophobic derivatives of glycopeptide antibiotics.
AID207010Antibacterial activity against glycopeptide intermediate resistant Staphylococcus aureus 3797 strain2003Journal of medicinal chemistry, Mar-27, Volume: 46, Issue:7
Role of the glycopeptide framework in the antibacterial activity of hydrophobic derivatives of glycopeptide antibiotics.
AID202122Minimum inhibitory concentration of compound was determined against Streptococcus pyogenes L 49 in mouse1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
Synthesis and antibacterial activity of a series of basic amides of teicoplanin and deglucoteicoplanin with polyamines.
AID152323Minimum inhibitory concentration against Proteus vulgaris ATCC 8811992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
Synthesis and antibacterial activity of a series of basic amides of teicoplanin and deglucoteicoplanin with polyamines.
AID206360Minimum inhibitory concentration against Staphylococcus epidermis L1378 evaluated in vitro1989Journal of medicinal chemistry, Apr, Volume: 32, Issue:4
Synthesis and biological evaluation of de(acetylglucosaminyl)didehydrodeoxy derivatives of teicoplanin antibodies.
AID739993Antimicrobial activity against VanB vancomycin-resistant Enterococcus faecalis ATCC 512992013Journal of medicinal chemistry, May-23, Volume: 56, Issue:10
Probing the role of the vancomycin e-ring aryl chloride: selective divergent synthesis and evaluation of alternatively substituted E-ring analogues.
AID163902Minimum inhibitory concentration against Pseudomonas aeruginosa ATCC 101451992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
Synthesis and antibacterial activity of a series of basic amides of teicoplanin and deglucoteicoplanin with polyamines.
AID227927Association constant of compound was evaluated at pH 51989Journal of medicinal chemistry, Apr, Volume: 32, Issue:4
Synthesis and biological evaluation of de(acetylglucosaminyl)didehydrodeoxy derivatives of teicoplanin antibodies.
AID68851In vitro minimum inhibitory concentration against Escherichia coli SKF 121401989Journal of medicinal chemistry, Nov, Volume: 32, Issue:11
Synthesis and biological properties of N63-carboxamides of teicoplanin antibiotics. Structure-activity relationships.
AID206829Minimum inhibitory concentration against Staphylococcus simulans L785 evaluated in vitro1989Journal of medicinal chemistry, Apr, Volume: 32, Issue:4
Synthesis and biological evaluation of de(acetylglucosaminyl)didehydrodeoxy derivatives of teicoplanin antibodies.
AID206828Minimum inhibitory concentration against Staphylococcus simulans L1142 evaluated in vitro1989Journal of medicinal chemistry, Apr, Volume: 32, Issue:4
Synthesis and biological evaluation of de(acetylglucosaminyl)didehydrodeoxy derivatives of teicoplanin antibodies.
AID206986Minimum inhibitory concentration against Staphylococcus warneri L1375 evaluated in vitro1989Journal of medicinal chemistry, Apr, Volume: 32, Issue:4
Synthesis and biological evaluation of de(acetylglucosaminyl)didehydrodeoxy derivatives of teicoplanin antibodies.
AID1201117Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as reduction of virus-induced cytopathic effect after 72 hrs by microscopic analysis2015European journal of medicinal chemistry, Apr-13, Volume: 94A few atoms make the difference: synthetic, CD, NMR and computational studies on antiviral and antibacterial activities of glycopeptide antibiotic aglycon derivatives.
AID1201116Cytotoxicity against MDCK cells after 72 hrs by MTS assay2015European journal of medicinal chemistry, Apr-13, Volume: 94A few atoms make the difference: synthetic, CD, NMR and computational studies on antiviral and antibacterial activities of glycopeptide antibiotic aglycon derivatives.
AID209621In vitro minimum inhibitory concentration against Streptococcus pyogenes C 2031989Journal of medicinal chemistry, Nov, Volume: 32, Issue:11
Synthesis and biological properties of N63-carboxamides of teicoplanin antibiotics. Structure-activity relationships.
AID739992Antimicrobial activity against VanA vancomycin-resistant Enterococcus faecalis BM41662013Journal of medicinal chemistry, May-23, Volume: 56, Issue:10
Probing the role of the vancomycin e-ring aryl chloride: selective divergent synthesis and evaluation of alternatively substituted E-ring analogues.
AID64587Minimum inhibitory concentration against Escherichia coli L 471992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
Synthesis and antibacterial activity of a series of basic amides of teicoplanin and deglucoteicoplanin with polyamines.
AID162779In vitro minimum inhibitory concentration against Pseudomonas aeruginosa ATCC 101451989Journal of medicinal chemistry, Nov, Volume: 32, Issue:11
Synthesis and biological properties of N63-carboxamides of teicoplanin antibiotics. Structure-activity relationships.
AID41087Association constant with Ac2-L-Lys-D-Ala-D-Ala1989Journal of medicinal chemistry, Nov, Volume: 32, Issue:11
Synthesis and biological properties of N63-carboxamides of teicoplanin antibiotics. Structure-activity relationships.
AID17258Association constant for compound at 31 degree C was determined1989Journal of medicinal chemistry, Feb, Volume: 32, Issue:2
Deaminoteicoplanin and its derivatives. Synthesis, antibacterial activity, and binding strength to Ac-D-Ala-D-Ala.
AID207218In vitro minimum inhibitory concentration against Staphylococcus aureus Tour1989Journal of medicinal chemistry, Nov, Volume: 32, Issue:11
Synthesis and biological properties of N63-carboxamides of teicoplanin antibiotics. Structure-activity relationships.
AID209118Minimum inhibitory concentration administered intravenously against Streptococcus pyogenes C203 in mouse1989Journal of medicinal chemistry, Apr, Volume: 32, Issue:4
Synthesis and biological evaluation of de(acetylglucosaminyl)didehydrodeoxy derivatives of teicoplanin antibodies.
AID209259Minimum inhibitory concentration against Streptococcus faecalis ATCC 7080 evaluated in vitro1989Journal of medicinal chemistry, Apr, Volume: 32, Issue:4
Synthesis and biological evaluation of de(acetylglucosaminyl)didehydrodeoxy derivatives of teicoplanin antibodies.
AID65374Minimum inhibitory concentration against Enterococcus faecalis ATCC 70801992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
Synthesis and antibacterial activity of a series of basic amides of teicoplanin and deglucoteicoplanin with polyamines.
AID201238Minimum inhibitory concentration against Staphylococcus aureus L 1651992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
Synthesis and antibacterial activity of a series of basic amides of teicoplanin and deglucoteicoplanin with polyamines.
AID201441Minimum inhibitory concentration against Staphylococcus epidermidis ATCC 122281992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
Synthesis and antibacterial activity of a series of basic amides of teicoplanin and deglucoteicoplanin with polyamines.
AID163393In vitro minimum inhibitory concentration against Proteus vulgaris X 19 ATCC 8811989Journal of medicinal chemistry, Nov, Volume: 32, Issue:11
Synthesis and biological properties of N63-carboxamides of teicoplanin antibiotics. Structure-activity relationships.
AID206231In vitro minimum inhibitory concentration against Staphylococcus epidermis ATCC 122281989Journal of medicinal chemistry, Nov, Volume: 32, Issue:11
Synthesis and biological properties of N63-carboxamides of teicoplanin antibiotics. Structure-activity relationships.
AID207534Minimal inhibitory concentration of compound against Staphylococcus aureus Tour in an inoculum of 10e6 cfu/mL1989Journal of medicinal chemistry, Feb, Volume: 32, Issue:2
Deaminoteicoplanin and its derivatives. Synthesis, antibacterial activity, and binding strength to Ac-D-Ala-D-Ala.
AID209405Minimal inhibitory concentration of compound against Streptococcus faecalis AACC70801989Journal of medicinal chemistry, Feb, Volume: 32, Issue:2
Deaminoteicoplanin and its derivatives. Synthesis, antibacterial activity, and binding strength to Ac-D-Ala-D-Ala.
AID1201121Antiviral activity against Influenza B virus (B/Hong Kong/05/1972) infected in MDCK cells assessed as reduction of virus-induced cytopathic effect after 72 hrs by microscopic analysis2015European journal of medicinal chemistry, Apr-13, Volume: 94A few atoms make the difference: synthetic, CD, NMR and computational studies on antiviral and antibacterial activities of glycopeptide antibiotic aglycon derivatives.
AID23284Partition coefficient (logD6.0) (1-butanol)1989Journal of medicinal chemistry, Nov, Volume: 32, Issue:11
Synthesis and biological properties of N63-carboxamides of teicoplanin antibiotics. Structure-activity relationships.
AID1201122Antiviral activity against Influenza B virus (B/Hong Kong/05/1972) infected in MDCK cells assessed as cell viability after 72 hrs by MTS assay2015European journal of medicinal chemistry, Apr-13, Volume: 94A few atoms make the difference: synthetic, CD, NMR and computational studies on antiviral and antibacterial activities of glycopeptide antibiotic aglycon derivatives.
AID206213Antibacterial activity against Staphylococcus epidermis 533 strain2003Journal of medicinal chemistry, Mar-27, Volume: 46, Issue:7
Role of the glycopeptide framework in the antibacterial activity of hydrophobic derivatives of glycopeptide antibiotics.
AID207532Minimal inhibitory concentration of compound against Staphylococcus aureus Tour1989Journal of medicinal chemistry, Feb, Volume: 32, Issue:2
Deaminoteicoplanin and its derivatives. Synthesis, antibacterial activity, and binding strength to Ac-D-Ala-D-Ala.
AID68068Antibacterial activity against glycopeptide resistant Enterococcus faecium 569 strain2003Journal of medicinal chemistry, Mar-27, Volume: 46, Issue:7
Role of the glycopeptide framework in the antibacterial activity of hydrophobic derivatives of glycopeptide antibiotics.
AID209587Antibacterial activity against Streptococcus haemolyticus 602 strain2003Journal of medicinal chemistry, Mar-27, Volume: 46, Issue:7
Role of the glycopeptide framework in the antibacterial activity of hydrophobic derivatives of glycopeptide antibiotics.
AID202121Minimum inhibitory concentration against Streptococcus pyogenes L 491992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
Synthesis and antibacterial activity of a series of basic amides of teicoplanin and deglucoteicoplanin with polyamines.
AID206022Minimum inhibitory concentration against Staphylococcus aureus Tour evaluated in vitro1989Journal of medicinal chemistry, Apr, Volume: 32, Issue:4
Synthesis and biological evaluation of de(acetylglucosaminyl)didehydrodeoxy derivatives of teicoplanin antibodies.
AID202095Minimum inhibitory concentration against Streptococcus pneumoniae L 441992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
Synthesis and antibacterial activity of a series of basic amides of teicoplanin and deglucoteicoplanin with polyamines.
AID1201118Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as cell viability after 72 hrs by MTS assay2015European journal of medicinal chemistry, Apr-13, Volume: 94A few atoms make the difference: synthetic, CD, NMR and computational studies on antiviral and antibacterial activities of glycopeptide antibiotic aglycon derivatives.
AID1201120Antiviral activity against Influenza A virus (A/Hong Kong/7/1987(H3N2)) infected in MDCK cells assessed as cell viability after 72 hrs by MTS assay2015European journal of medicinal chemistry, Apr-13, Volume: 94A few atoms make the difference: synthetic, CD, NMR and computational studies on antiviral and antibacterial activities of glycopeptide antibiotic aglycon derivatives.
AID1201115Cytotoxicity against MDCK cells after 72 hrs by microscopic analysis2015European journal of medicinal chemistry, Apr-13, Volume: 94A few atoms make the difference: synthetic, CD, NMR and computational studies on antiviral and antibacterial activities of glycopeptide antibiotic aglycon derivatives.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (39)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (10.26)18.7374
1990's4 (10.26)18.2507
2000's16 (41.03)29.6817
2010's14 (35.90)24.3611
2020's1 (2.56)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.74

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index17.74 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.64 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (17.74)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other34 (100.00%)84.16%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
carbamates
[no description available]		2.0210amino-acid anion
dimethyl sulfoxide
Dimethyl Sulfoxide: A highly polar organic liquid, that is used widely as a chemical solvent. Because of its ability to penetrate biological membranes, it is used as a vehicle for topical application of pharmaceuticals. It is also used to protect tissue during CRYOPRESERVATION. Dimethyl sulfoxide shows a range of pharmacological activity including analgesia and anti-inflammation.. dimethyl sulfoxide : A 2-carbon sulfoxide in which the sulfur atom has two methyl substituents.		2.1110sulfoxide;
volatile organic compound		alkylating agent;
antidote;
Escherichia coli metabolite;
geroprotector;
MRI contrast agent;
non-narcotic analgesic;
polar aprotic solvent;
radical scavenger
methanol
Methanol: A colorless, flammable liquid used in the manufacture of FORMALDEHYDE and ACETIC ACID, in chemical synthesis, antifreeze, and as a solvent. Ingestion of methanol is toxic and may cause blindness.. primary alcohol : A primary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has either three hydrogen atoms attached to it or only one other carbon atom and two hydrogen atoms attached to it.. methanol : The primary alcohol that is the simplest aliphatic alcohol, comprising a methyl and an alcohol group.		2.4920alkyl alcohol;
one-carbon compound;
primary alcohol;
volatile organic compound		amphiprotic solvent;
Escherichia coli metabolite;
fuel;
human metabolite;
mouse metabolite;
Mycoplasma genitalium metabolite
hypericin
[no description available]		2.0510
ifosfamide
[no description available]		2.0710ifosfamidesalkylating agent;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
xenobiotic
propranolol
Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.. propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.		2.0210naphthalenes;
propanolamine;
secondary amine		anti-arrhythmia drug;
antihypertensive agent;
anxiolytic drug;
beta-adrenergic antagonist;
environmental contaminant;
human blood serum metabolite;
vasodilator agent;
xenobiotic
pseudohypericin
pseudohypericin: structure given in first source		2.0510
vesamicol
vesamicol: RN given refers to parent cpd; structure		2.0510piperidines
vigabatrin
[no description available]		7.0510gamma-amino acidanticonvulsant;
EC 2.6.1.19 (4-aminobutyrate--2-oxoglutarate transaminase) inhibitor
zopiclone
zopiclone: S(+)-enantiomer of racemic zopiclone; azabicyclo(4.3.0)nonane; a nonbenzodiazepine; one of the so-called of Z drugs (zopiclone, eszopiclone, zolpidem, and zaleplon) for which there is some correlation with tumors; was term of zopiclone 2004-2007. zopiclone : A pyrrolo[3,4-b]pyrazine compound having a 4-methylpiperazine-1-carboxyl group at the 5-position, a 5-chloropyridin-2-yl group at the 6-position and an oxo-substituent at the 7-position.		2.2110monochloropyridine;
pyrrolopyrazine		central nervous system depressant;
sedative
adenosine diphosphate
Adenosine Diphosphate: Adenosine 5'-(trihydrogen diphosphate). An adenine nucleotide containing two phosphate groups esterified to the sugar moiety at the 5'-position.		2.0510adenosine 5'-phosphate;
purine ribonucleoside 5'-diphosphate		fundamental metabolite;
human metabolite
methionine
Methionine: A sulfur-containing essential L-amino acid that is important in many body functions.. methionine : A sulfur-containing amino acid that is butyric acid bearing an amino substituent at position 2 and a methylthio substituent at position 4.		2.4620aspartate family amino acid;
L-alpha-amino acid;
methionine zwitterion;
methionine;
proteinogenic amino acid		antidote to paracetamol poisoning;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical
acetonitrile
acetonitrile: RN given refers to unlabeled cpd. acetonitrile : A nitrile that is hydrogen cyanide in which the hydrogen has been replaced by a methyl group.		2.0310aliphatic nitrile;
volatile organic compound		EC 3.5.1.4 (amidase) inhibitor;
NMR chemical shift reference compound;
polar aprotic solvent
trifluoroacetic acid
Trifluoroacetic Acid: A very strong halogenated derivative of acetic acid. It is used in acid catalyzed reactions, especially those where an ester is cleaved in peptide synthesis.. trifluoroacetic acid : A monocarboxylic acid that is the trifluoro derivative of acetic acid.		2.2110fluoroalkanoic acidhuman xenobiotic metabolite;
NMR chemical shift reference compound;
reagent
perylene
Perylene: A 20-carbon dibenz(de,kl)anthracene that can be viewed as a naphthalene fused to a phenalene or as dinaphthalene. It is used as fluorescent lipid probe in the cytochemistry of membranes and is a polycyclic hydrocarbon pollutant in soil and water. Derivatives may be carcinogenic.. perylene : An ortho- and peri-fused polycyclic arene comprising of five benzene rings that is anthracene in which the d,e and k,l sides are fused to benzene rings.		2.0510ortho- and peri-fused polycyclic arene;
perylenes
phenylcarbamic acid
[no description available]		2.0210amino acid
vancomycin
Vancomycin: Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to RISTOCETIN that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.. vancomycin : A complex glycopeptide from Streptomyces orientalis. It inhibits a specific step in the synthesis of the peptidoglycan layer in the Gram-positive bacteria Staphylococcus aureus and Clostridium difficile.		3.470glycopeptideantibacterial drug;
antimicrobial agent;
bacterial metabolite
a 82846a
[no description available]		2.4420
fullerene c60
Fullerenes: A polyhedral CARBON structure composed of around 60-80 carbon atoms in pentagon and hexagon configuration. They are named after Buckminster Fuller because of structural resemblance to geodesic domes. Fullerenes can be made in high temperature such as arc discharge in an inert atmosphere.. fullerene : A compound composed solely of an even number of carbon atoms, which form a cage-like fused-ring polycyclic system with twelve five-membered rings and the rest six-membered rings. The term has been broadened to include any closed cage structure consisting entirely of three-coordinate carbon atoms.		2.0710fullerenegeroprotector
adenosine 3'-phosphate-5'-phosphate
adenosine 3',5'-bismonophosphate : An adenosine bisphosphate having two monophosphate groups at the 3'- and 5'-positions.		2.0510adenosine bisphosphateEscherichia coli metabolite;
mouse metabolite
18-crown-6 2,3,11,12-tetracarboxylic acid
18-crown-6 2,3,11,12-tetracarboxylic acid: structure in first source; RN given for (2R*,3R*,11*,12*)-isomer		2.0110
mdl 62873
[no description available]		1.9710
ristocetin
Ristocetin: An antibiotic mixture of two components, A and B, obtained from Nocardia lurida (or the same substance produced by any other means). It is no longer used clinically because of its toxicity. It causes platelet agglutination and blood coagulation and is used to assay those functions in vitro.. ristocetin : A heterodetic cyclic peptide that is produced by species of Amycolatopsis and Nocardia.		3.1250glycopeptide;
heterodetic cyclic peptide;
macrocycle;
tetrasaccharide derivative		antibacterial drug;
antimicrobial agent;
bacterial metabolite;
platelet-activating factor receptor agonist
cellulose
DEAE-Cellulose: Cellulose derivative used in chromatography, as ion-exchange material, and for various industrial applications.		2.0510glycoside
piperidines
Piperidines: A family of hexahydropyridines.		2.0510
amantadine
amant: an antiviral compound consisting of an adamantane derivative chemically linked to a water-solube polyanioic matrix; structure in first source		2.1110adamantanes;
primary aliphatic amine		analgesic;
antiparkinson drug;
antiviral drug;
dopaminergic agent;
NMDA receptor antagonist;
non-narcotic analgesic
rimantadine
Rimantadine: An RNA synthesis inhibitor that is used as an antiviral agent in the prophylaxis and treatment of influenza.		2.1110alkylamine
vancomycin
Vancomycin: Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to RISTOCETIN that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.. vancomycin : A complex glycopeptide from Streptomyces orientalis. It inhibits a specific step in the synthesis of the peptidoglycan layer in the Gram-positive bacteria Staphylococcus aureus and Clostridium difficile.		2.4420glycopeptideantibacterial drug;
antimicrobial agent;
bacterial metabolite
ribavirin
Rebetron: Rebetron is tradename		2.11101-ribosyltriazole;
aromatic amide;
monocarboxylic acid amide;
primary carboxamide		anticoronaviral agent;
antiinfective agent;
antimetabolite;
antiviral agent;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
oseltamivir
Oseltamivir: An acetamido cyclohexene that is a structural homolog of SIALIC ACID and inhibits NEURAMINIDASE.. oseltamivir : A cyclohexenecarboxylate ester that is the ethyl ester of oseltamivir acid. An antiviral prodrug (it is hydrolysed to the active free carboxylic acid in the liver), it is used to slow the spread of influenza.		2.1110acetamides;
amino acid ester;
cyclohexenecarboxylate ester;
primary amino compound		antiviral drug;
EC 3.2.1.18 (exo-alpha-sialidase) inhibitor;
environmental contaminant;
prodrug;
xenobiotic
a 82846a
[no description available]		2.0110
eremomycin aglycone
[no description available]		2.0110
aglucovancomycin b
aglucovancomycin B: degradation product of vancomycin B; structure in first source. vancomycin aglycone : A peptide antibiotic that is vancomycin lacking the disaccharide moiety.		2.0810cyclic ether;
heterodetic cyclic peptide;
peptide antibiotic;
peptide zwitterion;
polyphenol		metabolite
ConditionIndicatedRelationship StrengthStudiesTrials
Sensitivity and Specificity
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)		02.0510
Blood Poisoning
[description not available]		01.9710
Group A Strep Infection
[description not available]		02.8940
Streptococcal Infections
Infections with bacteria of the genus STREPTOCOCCUS.		02.8940
Sepsis
Systemic inflammatory response syndrome with a proven or suspected infectious etiology. When sepsis is associated with organ dysfunction distant from the site of infection, it is called severe sepsis. When sepsis is accompanied by HYPOTENSION despite adequate fluid infusion, it is called SEPTIC SHOCK.		01.9710
E coli Infections
[description not available]		01.9810
Escherichia coli Infections
Infections with bacteria of the species ESCHERICHIA COLI.		01.9810
Bacteremia
The presence of viable bacteria circulating in the blood. Fever, chills, tachycardia, and tachypnea are common acute manifestations of bacteremia. The majority of cases are seen in already hospitalized patients, most of whom have underlying diseases or procedures which render their bloodstreams susceptible to invasion.		01.9810